Brenntag Specialties Announces Exclusive Distribution Agreement With MEGGLE Excipients For Pharmaceutical-Grade Lactose In Benelux And Nordics

• Pharma lactose will be reliably available to customers in the Netherlands, Belgium, Norway, Finland and Sweden.
• With this distribution agreement, Brenntag expands its portfolio with high-quality excipients for a variety of pharmaceutical applications, including Tableting, Powder preparations, and Dry Powder Inhalation (DPI).

Brenntag, the global market leader in the distribution of chemicals and ingredients, today announced a strategic partnership with MEGGLE Excipients, a leading manufacturer of pharmaceutical excipients. As part of this collaboration, a broad portfolio of lactose-based excipients will be available from the beginning of February. This portfolio comprises more than 30 high-quality products for various applications in the pharmaceutical industries in the Netherlands, Belgium, Norway, Finland and Sweden.

These high-grade lactose-based excipients are versatile and offer optimal solutions for a wide range of pharmaceutical applications, including tableting (granulation and direct compression), powder preparations, and Dry Powder Inhalation. With the variety of available grades, specific formulation requirements can be precisely met, ensuring high flexibility and efficiency in product development and manufacturing.

Joakim Rehné, Brenntag Specialties President Pharma EMEA, states: “Customers are now supplied by us with lactose excipients of the highest quality, which are required to produce effective pharmaceuticals. The expanded product range strengthens our role as a key supplier to the global healthcare industry.”

Ruth Leinenbach, Director BU Excipients at MEGGLE, says: “This partnership enables us to make our excipients even more accessible to our customers. With Brenntag s' extensive logistics network, proven expertise, and reliable infrastructure, we can ensure consistent and efficient delivery.”

About MEGGLE:
MEGGLE Group GmbH with its headquarter in the Bavarian city of Wasserburg (Germany), operates as a foundation for various business activities in the dairy industry and whey processing. MEGGLE has a proud history of more than 135 years in the dairy market. The Business Unit Excipients produces pharmaceutical excipients for direct compression, granulation, capsules, sachets, powder blends and dry powder inhalers. With its broad product portfolio, intelligent innovations, and exceptional product quality, MEGGLE plays a leading role in the global pharmaceutical excipients business. With production facilities in Wasserburg (Germany) and Le Sueur, Minnesota (USA), where the requirements of the North American market are served, MEGGLE is prepared to meet customer expectations worldwide. For more information, visit www.meggle-excipients.com